C. Sirolla

发表

Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.

R. Testa, A. Bonfigli, C. Sirolla, 2004, Diabetes, nutrition & metabolism.

The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study

R. Testa, A. Bonfigli, C. Sirolla, 2013, Acta Diabetologica.

Psychological, neuroendocrine and immune measures in non spousal carers of disabled elderly in Italy.

C. Sirolla, M. Melchiorre, G. Lamura, 2004, Neuro endocrinology letters.

Asymptomatic Helicobacter pylori Infection Increases Asymmetric Dimethylarginine Levels in Healthy Subjects

R. Testa, A. Bonfigli, C. Sirolla, 2005, Helicobacter.

Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction.

R. Testa, A. Bonfigli, C. Sirolla, 2009, Atherosclerosis.

The PON1192RR genotype is associated with a higher prevalence of arterial hypertension

R. Testa, C. Sirolla, M. Boemi, 2006, Journal of Hypertension.

Endovascular Repair of Thoracic Aortic Disease with the EndoFit Stent-Graft: Short and Midterm Results from a Single Center

C. Sirolla, M. Pavesi, M. Medda, 2008, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

The Pro/Pro genotype of the p53 codon 72 polymorphism modulates PAI-1 plasma levels in ageing

R. Testa, A. Bonfigli, C. Sirolla, 2009, Mechanisms of Ageing and Development.

Interleukin-6-174 G > C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients.

R. Testa, A. Bonfigli, C. Sirolla, 2006, Diabetes research and clinical practice.

Apolipoprotein E Polymorphism as a Risk Factor for Vascular Disease in Diabetic Patients

C. Sirolla, M. Boemi, R. James, 1995, Diabetes Care.

A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications

R. Testa, A. Bonfigli, C. Sirolla, 1998, International journal of clinical & laboratory research.

Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects.

R. Testa, A. Bonfigli, C. Sirolla, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

+647 A/C and +1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications.

R. Testa, A. Bonfigli, C. Sirolla, 2008, Molecular genetics and metabolism.

Helicobacter pylori masks differences in homocysteine plasma levels between controls and type 2 diabetic patients

R. Testa, A. Bonfigli, C. Sirolla, 2002, European journal of clinical investigation.

Lipoprotein (a) and vascular disease in diabetic patients

C. Sirolla, M. Boemi, R. James, 1995, Diabetologia.

Lipoprotein(a) and Retinopathy in IDDM and NIDDM Patients

C. Sirolla, M. Boemi, R. James, 1997, Diabetes Care.

Plasminogen activator inhibitor-1 plasma level increases with age in subjects with the 4G allele at position -675 in the promoter region

A. Bonfigli, C. Sirolla, M. Boemi, 2004, Thrombosis and Haemostasis.

Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.

R. Testa, C. Sirolla, M. Boemi, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation.

C. Sirolla, M. Boemi, C. Pieri, 2001, Atherosclerosis.

Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients

C. Sirolla, M. Boemi, R. Testa, 2004, Diabetic medicine : a journal of the British Diabetic Association.

Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.

R. Testa, A. Bonfigli, C. Sirolla, 2000, Diabetes, nutrition & metabolism.

A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.

R. Testa, A. Bonfigli, C. Sirolla, 1999, Diabetes, nutrition & metabolism.

Platelet nitric oxide production and IR: relation with obesity and hypertriglyceridemia.

R. Testa, C. Sirolla, L. Mazzanti, 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Apolipoprotein E polymorphisms and mortality in Italian Type 2 diabetic patients

C. Sirolla, M. Boemi, G. Brandoni, 2003, European journal of clinical investigation.

Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes

Gastone Castellani, Daniela Mari, Claudio Franceschi, 2011, AGE.

Mitochondrial DNA Backgrounds Might Modulate Diabetes Complications Rather than T2DM as a Whole

R. Testa, A. Bonfigli, C. Sirolla, 2011, PloS one.

Helicobacter pylori and atrial fibrillation: a possible pathogenic link

C. Sirolla, A. Antonelli, A. Dolci, 2005, Heart.

Leukocyte telomere length is associated with complications of Type 2 diabetes mellitus

R. Testa, A. Bonfigli, C. Sirolla, 2011, Diabetic medicine : a journal of the British Diabetic Association.

Relationship between lipoprotein(a) levels, oxidative stress, and blood pressure levels in patients with essential hypertension

R. Testa, A. Bonfigli, C. Sirolla, 2001, Clinical and Experimental Medicine.

A study on the action of vitamin E supplementation on plasminogen activator inhibitor type 1 and platelet nitric oxide production in type 2 diabetic patients.

R. Testa, C. Sirolla, S. Manfrini, 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.

R. Testa, A. Bonfigli, C. Sirolla, 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes

G. Castellani, R. Testa, C. Sirolla, 2013, AGE.

Development and validation of the HOPE prognostic index on 24-month posthospital mortality and rehospitalization: Italian National Research Center on Aging (INRCA).

C. Sirolla, A. Corsonello, A. Abbatecola, 2011, Rejuvenation research.

Effect of Etanercept on Insulin Sensitivity in Nine Patients with Psoriasis

R. Testa, A. Bonfigli, C. Sirolla, 2007, International journal of immunopathology and pharmacology.

Combination of biomarkers to predict mortality in elderly patients with myocardial infarction

C. Sirolla, C. Franceschi, M. Cardelli, 2008, Mechanisms of Ageing and Development.

Work restrictions experienced by midlife family care-givers of older people: evidence from six European countries

Barbro Krevers, Giovanni Lamura, C. Sirolla, 2012, Ageing and Society.

Reproducibility of normal facial motor nerve conduction studies and their relevance in the electrophysiological assessment of peripheral facial paralysis

C. Sirolla, L. Provinciali, F. Logullo, 1997, Neurophysiologie Clinique/Clinical Neurophysiology.

Renal disease as a determinant of increased lipoprotein(a) concentrations in diabetic patients.

C. Sirolla, M. Boemi, R. James, 1999, Diabetes care.